A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Completed · Phase 2 · NCT05936151
Conditions: Overweight or Obesity, CKD, Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $2.4M
- U.S. investigators named
- 22
- Sites paid
- 19
- Planned or actual enrollment
- 146
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Retatrutide (drug), Placebo (drug)
- Dates
- Started 2023-07-20; completion 2025-10-21
- Results posted
- Yes
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.4M in research payments for this study in 2025 (26 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Donna M. Desantis, MD Family Medicine · Mesa, AZ
- Jeffrey R. Hoodin, M.D. Internal Medicine · Tempe, AZ
- Yessica R. Sachdeva, M.D. Internal Medicine · Mesa, AZ
- Hessam Aazami, M.D. General Practice · Canoga Park, CA
- Rizwana Mohseni, D.O. Family Medicine · Lake Forest, CA
- Lawrence D. Sher, M.D. Pediatrics · Rolling Hills Estates, CA
- Melanie G. Cree, MD, PHD Pediatric Endocrinology · Aurora, CO
- Viralkumar N. Shah, MD Endocrinology & Diabetes · Aurora, CO
- Daniel G. Lorch, M.D. Pulmonology · Brandon, FL
- Visal Numrungroad, M.D. Nephrology (Kidney) · New Port Richey, FL
- Khaleel Sayeed, M.D. Nephrology (Kidney) · Chicago, IL
- Maria L. Caramori, MD Endocrinology & Diabetes · Minneapolis, MN
- Samer Nakhle, MD Endocrinology & Diabetes · Las Vegas, NV
- Naveed Masani, M.D. Nephrology (Kidney) · Mineola, NY
- Andrew N. Abboud Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Vincent Chen, MD Cardiology · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Samuel Kelly, MD Cardiology · Philadelphia, PA
- Abdul A. Abdellatif, M.D. Nephrology (Kidney) · Webster, TX
- Amer Al-karadsheh, M.D. Endocrinology & Diabetes · Houston, TX
- Ankur A. Doshi, M.D. Internal Medicine · Houston, TX
- Brandon Lawrence, M.D. Orthopedic Surgery · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Elligo Health Research Inc $794,505
- Medical Advancement Centers of Arizona LLC $377,109
- Tranquil Clinical and Research $140,036
- Victorium Clinical Research LTD Co $121,170
- Endocrine Ips PLLC $114,647
- Great Lakes Clinical Trials $111,015
- Cleveland Clinic, OH $96,836
- New York University $94,551
- Headlands Horizons LLC $94,492
- Suncoast Clinical Research $90,402
- Peninsula Headlands LLC $79,513
- Teradan Clinical Trials LLC $63,474
- Regents of the University of Colorado $54,773
- Catalina Research Institute LLC $36,379
- Care Access Research LLC $34,078
- Institute for Liver Health LLC $30,492
- Palm Research Center Inc $26,650
- Indiana University $10,630
- Clinical Trial Source LLC $1,174
- $238
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.